Literature DB >> 11595751

Exploitation of the HIV-1 coat glycoprotein, gp120, in neurodegenerative studies in vivo.

M T Corasaniti1, M Maccarrone, R Nistico, W Malorni, D Rotiroti, G Bagetta.   

Abstract

Neuronal loss has often been described at post-mortem in the brain neocortex of patients suffering from AIDS. Neuroinvasive strains of HIV infect macrophages, microglial cells and multinucleated giant cells, but not neurones. Processing of the virus by cells of the myelomonocytic lineage yields viral products that, in conjunction with potentially neurotoxic molecules generated by the host, might initiate a complex network of events which lead neurones to death. In particular, the HIV-1 coat glycoprotein, gp120, has been proposed as a likely aetiologic agent of the described neuronal loss because it causes death of neurones in culture. More recently, it has been shown that brain neocortical cell death is caused in rat by intracerebroventricular injection of a recombinant gp120 coat protein, and that this occurs via apoptosis. The latter observation broadens our knowledge in the pathophysiology of the reported neuronal cell loss and opens a new lane of experimental research for the development of novel therapeutic strategies to limit damage to the brain of patients suffering from HIV-associated dementia.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11595751     DOI: 10.1046/j.1471-4159.2001.00537.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  8 in total

1.  The HIV-1 coat protein gp120 regulates CXCR4-mediated signaling in neural progenitor cells.

Authors:  Phuong B Tran; Dongjun Ren; Richard J Miller
Journal:  J Neuroimmunol       Date:  2004-12-28       Impact factor: 3.478

2.  Human immunodeficiency virus-associated dementia: a link between accumulation of viral proteins and neuronal degeneration.

Authors:  Italo Mocchetti; Alessia Bachis; Giuseppe Esposito; Scott R Turner; Francesca Taraballi; Ennio Tasciotti; Mikell Paige; Valeriya Avdoshina
Journal:  Curr Trends Neurol       Date:  2014

3.  Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists.

Authors:  Antonella Bugatti; Cinzia Giagulli; Chiara Urbinati; Francesca Caccuri; Paola Chiodelli; Pasqua Oreste; Simona Fiorentini; Alessandro Orro; Luciano Milanesi; Pasqualina D'Ursi; Arnaldo Caruso; Marco Rusnati
Journal:  J Biol Chem       Date:  2012-11-19       Impact factor: 5.157

4.  Carbohydrates: Binding Sites and Potential Drug Targets for Neural-Affecting Pathogens.

Authors:  Cara-Lynne Schengrund
Journal:  Adv Neurobiol       Date:  2023

5.  Heparin-mimicking sulfonic acid polymers as multitarget inhibitors of human immunodeficiency virus type 1 Tat and gp120 proteins.

Authors:  Antonella Bugatti; Chiara Urbinati; Cosetta Ravelli; Erik De Clercq; Sandra Liekens; Marco Rusnati
Journal:  Antimicrob Agents Chemother       Date:  2007-04-23       Impact factor: 5.191

6.  Neonatal intrahippocampal HIV-1 protein Tat(1-86) injection: neurobehavioral alterations in the absence of increased inflammatory cytokine activation.

Authors:  Landhing M Moran; Sylvia Fitting; Rosemarie M Booze; Katy M Webb; Charles F Mactutus
Journal:  Int J Dev Neurosci       Date:  2014-10-05       Impact factor: 2.457

7.  The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis.

Authors:  Hava Karsenty Avraham; Shuxian Jiang; Yigong Fu; Edward Rockenstein; Alexandros Makriyannis; Alexander Zvonok; Eliezer Masliah; Shalom Avraham
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

8.  N-acetylcysteine prevents HIV gp 120-related damage of human cultured astrocytes: correlation with glutamine synthase dysfunction.

Authors:  Valeria Visalli; Carolina Muscoli; Iolanda Sacco; Francesca Sculco; Ernesto Palma; Nicola Costa; Carmela Colica; Domenicantonio Rotiroti; Vincenzo Mollace
Journal:  BMC Neurosci       Date:  2007-12-06       Impact factor: 3.288

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.